Risankizumab
Products Risankizumab was approved in the United States and in many countries in 2019 as a solution for injection (Skyrizi). Structure and properties Risankizumab is a humanized IgG1 monoclonal antibody produced by biotechnological methods. Effects Risankizumab (ATC L04AC) has selective immunosuppressive and anti-inflammatory properties. The antibody binds to the p19 subunit of human interleukin-23 (IL-23), … Risankizumab